BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc. is pleased to announce the publication of two therapeutic cancer vaccine Phase 1 studies in Clinical Cancer Research (volume 18(3), pages 1-11). In the article, which was featured as one of the highlights of the issue, Dr. Dung Le et al. reported that intravenous administration of ANZ-100 and CRS-207 was well tolerated in subjects with advanced, treatment-refractory cancers. Le et al. also reported evidence of immune activation, induction of tumor-specific immunity and that 37% of end-stage cancer subjects treated with CRS-207 lived 15 months or longer.
